Skip to main content
. 2023 Mar 28;12:e83694. doi: 10.7554/eLife.83694

Figure 2. Immunogenicity of the fourth dose of coronavirus disease 2019 (COVID-19) vaccine in cancer patients with seronegativity after three doses.

Figure 2.

(A) Anti-spike IgG levels after the fourth dose of COVID-19 vaccine for the entire cohort n=18. (B) Correlation of baseline IgM levels with response to fourth dose of vaccine, n=18 Kruskal-Wallis test. (C) Line diagram showing correlation between anti-SARS-CoV-2 (anti-S) titer and neutralization activity for wild-type (WT) virus at baseline and 4 weeks, n=18, Spearman’s test. (D) Line diagram showing correlation between titer and neutralization activity for Omicron strain at baseline and 4 weeks n=18, Spearman’s test. All statistical tests performed at a pre-determined threshold of p<0.05 for statistical significance.